Board summary
Key figures
88,617
Registered population
75.5% aged 18–64
6.4%
Aged 65+
ICB 14.9% · England 17.9%
56.7%
Ethnic minority (non-White)
35.2% Asian · England 9.6%
72.8%
In IMD quintile 1
ICB 40.7% · England 21.0%
~32,691
Core20 residents (est.)
Resident basis; registered basis ~60,282 · see page 3
7,749
Hypertension register
+5.84% in 3 yrs · England +5.60%
976
SMI register
10.3% of Manchester (LAD)'s
1,039
COPD register
Reviews -18.66% in 3 yrs
Forecast to 2030
8,720
Hypertension patients, 2030
+971 on today
82.9%
QRISK ≥20% on statins, 2030
+3.12pp over 3 yrs
1.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Respiratory reviews fall as COPD register grows.
Annual COPD reviews changed -18.7% to 66.0% (England 76.4%) despite +8.5% register growth, while 1,579 asthma patients lack a recorded review.
Cervical screening and age-five boosters lag.
Cervical screening in ages 25-49 is 43.7% (England 66.8%, 3-year change -5.8%), and age-5 MMR2 is 67.0% versus 89.2% for MMR1 (22.2 pp difference).
Statin prescribing and SMI checks beat comparators.
Lipid-lowering therapy for QRISK ≥ 20% reaches 76.3% (England 63.6%, Manchester 70.5%, ICB 67.0%), while SMI BP and BMI checks both reach 83.8%.
Population, age and ethnicity
A registered list of 88,617 has 75.5% aged 18-64 and 6.4% aged 65+
Across member practices, the PCN has 88,617 registered patients. The population is working-age: 75.5% (66,887 patients) are aged 18-64, exceeding Manchester (LAD) at 68.9%, NHS Greater Manchester Integrated Care Board at 63.3% and England at 62.7%. Only 6.4% (5,676 patients) are aged 65+, below Manchester (9.6%), the ICB (14.9%) and England (17.9%). By Census usual-resident estimates, not registered patients, 56.7% are from ethnic minority groups, led by Asian or Asian British residents at 35.2% (Manchester 20.9%, England 9.6%), reaching 62.8% at Parkside Surgery and 51.3% at Dickenson Road Medical Centre.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Manchester LA) | 2,357 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Manchester LA) | 1,281 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Manchester LA) | 26.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 72.8% of the PCN, with practice shares spanning 76.5 pp
Core20 patients make up 72.8% of the PCN, above Manchester (59.8%), the ICB (40.7%) and England (21.0%), with an average IMD decile of 2.4 (England 5.5). Practice Core20 shares span 76.5 pp, from 23.5% at Vallance Medical to 100.0% at Parkside Surgery. Denominators diverge: the resident Core20 estimate is 32,691 while practice-summed registered estimates reach 60,282 (weighted practice share 68.0%). Targeting by Core20 concentration highlights Parkside Surgery (100.0%), whereas volume targeting points to Manchester Integrative Medical Practice (10,828 patients).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
976
SMI register
1.05% recorded prevalence
566
Learning disability register
0.61% recorded prevalence
13
Care homes, 243 beds
In the PCN catchment
8.7%
Provide unpaid care
Manchester (LAD), Census 2021
The PCN records 976 patients on the severe mental illness register (1.1%) and 566 on the learning disability register (0.6%), alongside 13 catchment care homes (243 beds). At local authority level, Manchester recorded 55 rough sleepers in the autumn 2025 snapshot, whereas PCN-level homelessness counts were not captured.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reached 83.8% (England 83.4%) and BMI recording reached 83.8% (England 82.1%), while alcohol recording reached 84.9% (England 81.8%). Other check elements were not captured; published rates cannot establish full check completion.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,749
Hypertension register
+5.84%
Register growth, 3 yrs
Manchester (LAD) +4.49% · England +5.60%
+0.75pp
BP control, under 80
≤140/90 · +1.22pp aged 80+
+971
More patients by 2030
Forecast 8,720 (9.31%)
Hypertension case-finding and control
Ardwick and Longsight PCN records a hypertension prevalence of 8.3% (7,749 patients), below Manchester (10.5%), the ICB (14.4%) and England (15.2%), though crude recorded prevalence does not establish under-detection in a population where 75.5% are aged 18-64. Recent blood pressure checks reach 90.2% (England 90.0%). Blood pressure control to <= 140/90 mmHg in patients aged under 80 reaches 66.2%, trailing the ICB (68.6%) and England (67.8%), with three-year growth of +1.1% lagging England (+3.2%). Blood pressure treated to target sits at 68.4% (England 70.3%, ICB 71.4%). Blood pressure control among patients under 80 lags regional and national benchmarks.
Lipids and statins
Patients with QRISK ≥ 20% treated with lipid lowering therapy reach 76.3% (England 63.6%, Manchester 70.5%, ICB 67.0%). Among patients with diabetes aged 40 and over without cardiovascular disease, statin treatment is 84.6% (England 73.2%, Manchester 79.8%, ICB 75.7%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 125,825 | £3.40 | £1.94 | £1.86 | £427,805 |
| Cardiovascular (all), 2025 | 138,415 | £2.32 | £3.15 | £3.33 | £321,123 |
Lipid-regulating drugs cost £3.40 per item in 2026 across 125,825 items (£427,805 spend), compared to £1.86 for England and £1.94 for NHS Greater Manchester Integrated Care Board. Across 125,825 items, this represents £193,770 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−3.20%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−3.23%
Asthma prevalence, PCN 3-yr % change
The COPD register grew +8.5% over 2023 to 2025 (England +2.6%) to 1,039 patients, while annual COPD reviews fell 18.7% (England +2.8%) to 66.0% (England 76.4%, Manchester 74.5%, ICB 76.4%). Asthma reviews fell 3.2% over 2023 to 2025 (England +4.4%) to 61.8% (England 65.7%), leaving about 1,600 patients unreviewed across 4,135 on the register. Second-hand smoking recording for asthma patients aged 6-19 is 66.2% (England 78.8%).
Cancer register and children's immunisation
Recorded cancer prevalence is 1.3% (England 3.8%). In Q1 2025/26, age-5 MMR coverage was 89.2% for dose 1 but 67.0% for dose 2 (England 82.8%), a 22.2 pp difference. The 4-in-1 booster coverage at age 5 reached 63.1% (England 80.9%, ICB 80.5%). At 12 months, 6-in-1 coverage reached 81.4% (England 91.0%, ICB 88.7%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 staged cases), in line with England (55.3%) but below the 75.0% national ambition by 19.4 pp. Reaching that ambition would require about 2,270 additional early-stage diagnoses annually across the ICB, where known-stage coverage was 70.8% (11,679 of 16,492 registered cancers). These system-level figures do not represent PCN performance. However, PCN cervical screening coverage in women aged 25-49 is 43.7% (England 66.8%, Manchester 57.2%, ICB 65.9%), having fallen -5.8% over three years. Persistent screening shortfalls may delay early detection and leave symptom presentation to later stages.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Manchester University NHS Foundation Trust, the 62-day referral to treatment performance was 72.8%, falling below the 85.0% standard by 12.2 pp, compared to 75.7% across NHS Greater Manchester Integrated Care Board (9.3 pp below standard). The trust met the 28-day faster diagnosis standard at 80.1% (5.1 pp above the 75.0% standard; ICB 79.5%), but trailed the 31-day combined treatment standard at 92.5% (below the 96.0% standard by 3.5 pp). These acute operational pressures indicate that while initial diagnosis is prompt, treatment commencement faces secondary-care pathway delays. Secondary-care treatment backlogs mean practice teams must actively monitor referred patients awaiting definitive.
| Pathways within standard (%) | Manchester | Northern Care Alliance | Stockport | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 83.21 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 97.39 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 74.67 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Stockport | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 1.41 | 21.40 |
| CT | 14.66 | 4.10 | 2.93 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 17.46 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 5.53 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 5.31 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 14.08 | 23.14 |
| Community services activity | Manchester residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 96,995 | 573,310 |
| Referrals | 20,270 | 94,470 |
| Patients with a contact | 31,040 | 183,535 |
Community services (residents of Manchester), Jun 2026 (provisional). In provisional Community Services Dataset reporting for June 2026, adults aged 65 and over accounted for 43.3% of community contacts among Manchester borough residents (42,015 of 96,995 contacts). These activity data reflect borough-level community service delivery rather than PCN-specific utilization, underscoring substantial older-adult community resource use across the wider municipal area. Older-adult community contact volume suggests community nurse liaison is vital when supporting frail patients undergoing cancer investigations.
Practice variation and patient experience
Practice patient satisfaction ranges from 67.3% to 93.3%, alongside variable QOF adjustment rates
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Brunswick Medical | 115 | 57.9 | 80.9% | 74.4% | 93.3% |
| Ardwick Medical | 107 | 79.1 | 59.6% | 90.0% | 81.5% |
| Vallance Medical | 60 | 23.5 | 85.0% | 70.9% | 81.3% |
| Surrey Lodge | 110 | 48.4 | 63.8% | 67.4% | 81.0% |
| Wilmslow Road | 87 | 46.9 | 62.5% | 71.5% | 80.8% |
| Manchester | 101 | 77.0 | 55.4% | 73.4% | 78.2% |
| Ailsa Craig | 79 | 86.4 | 31.1% | 72.3% | 74.0% |
| New Bank Health | 70 | 97.1 | 56.5% | 70.8% | 72.1% |
| Dickenson Road | 104 | 97.9 | 43.5% | 74.4% | 68.7% |
| Parkside Surgery | 64 | 100.0 | 48.0% | 83.5% | 67.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 tracked three-year trends trailed England despite gains in mental health checks
Across 25 tracked measures, 15 three-year trends trailed England. The widest lags were in routine reviews: COPD reviews fell 18.7% (England +2.8%) and asthma reviews fell 3.2% (England +4.4%), while learning disability prevalence fell 6.0% (England +5.4%). Conversely, severe mental illness checks showed progress (+5.4 pp for blood pressure, England +4.4 pp; +5.7 pp for BMI, England +5.1 pp) to reach 83.8% for both. Non-frail diabetes HbA1c control also improved (+4.8%, England +4.4%) to 55.8%.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Learning disability register
Asthma reviews
Heart failure reviews
Cervical screening
Breast screening (53-70)
BP check (SMI)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Manchester (LAD) | Asset | PCN | Manchester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (243 beds) | n/a | Schools (catchment) | 90 | n/a |
| Children's centres | 8 | 34 | Places of worship | 75 | 289 |
| Libraries | 4 | 16 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 18 | 68 | Primary academies | 4 | 50 |
| Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and COPD review recall
Asthma reviews are 61.8% (England 65.7%; 3-year change -3.2% vs +4.4%), leaving 1,579 of 4,135 patients unreviewed; COPD reviews fell 18.7% to 66.0% (England 76.4%) across 1,039 patients. For discussion: run single-template recall and after-school asthma review slots alongside second-hand smoke recording (66.2% vs England 78.8%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension titration and lipid prescribing review
Under-80s BP control is 66.2% (England 67.8%, ICB 68.6%; 3-year change +1.1% vs England +3.2%); lipid-modifying prescribing costs £3.40 per item, or £193,770 more than at England's £1.86 unit cost across 125,825 items. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Culturally adapted screening and booster recall
Cervical screening (ages 25-49) is 43.7% (England 66.8%; 3-year change -5.8%); age-5 MMR2 is 67.0% versus 89.2% for MMR1 (22.2 pp difference, England 82.8%), and 4-in-1 booster coverage is 63.1% (England 80.9%). Moderate effort to run.
Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.
Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Dual track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Sustain physical health monitoring (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake recovery (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Targeted patient access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma and COPD review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension titration and lipid prescribing review (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Culturally adapted screening and booster recall (p12) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) · Breast screening coverage: aged 53 to 70 years old · Asian / Asian British | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
